Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

(2014) Nayyar Iqbal et al.   Cardiovascular Diabetology

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

(2013) W. B. White et al.   DIABETES OBESITY & METABOLISM

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes: Practical lessons from ACCORD and other cardiovascular trials

(2012) M. C. Riddle et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

(2012) M. Monami et al.   DIABETES OBESITY & METABOLISM

Cardiovascular Biology of the Incretin System

(2012) John R. Ussher et al.   ENDOCRINE REVIEWS

Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats

(2012) R. Preston Mason et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers

(2012) Ashish Kumar Gupta et al.   PLATELETS

Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice

(2011) J. Shirakawa et al.   DIABETES

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes

(2011) P. C. M. van Poppel et al.   DIABETES CARE

Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs

(2011) B. Hirshberg et al.   DIABETES CARE

Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up: Lessons from the San Luigi Gonzaga Diabetes Study

(2011) F. Cavalot et al.   DIABETES CARE

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes

(2011) A. J. Tremblay et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

(2011) Nelson Gomez et al.   EUROPEAN JOURNAL OF HEART FAILURE

Apolipoprotein CIII Links Dyslipidemia with Atherosclerosis

(2011) Akio Kawakami et al.   Journal of Atherosclerosis and Thrombosis

Effect of Enhanced Glycemic Control with Saxagliptin on Endothelial Nitric Oxide Release and CD40 Levels in Obese Rats

(2011) R. Preston Mason et al.   Journal of Atherosclerosis and Thrombosis

DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

(2011) Nga N Ta et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis

(2011) Takanori Matsui et al.   PHARMACOLOGICAL RESEARCH

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

(2010) A. D. Dobrian et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling

(2010) Ulrich Förstermann et al.   BRITISH JOURNAL OF PHARMACOLOGY

DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease

(2010) Philip A. Read et al.   Circulation-Cardiovascular Imaging

Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase–Mediated, Nitric Oxide–Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy

(2010) Siva Bhashyam et al.   Circulation-Heart Failure

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1 

(2010) G. P. Fadini et al.   DIABETES CARE

Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes

(2010) J. Koska et al.   DIABETES CARE

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

(2010) M. A. Nauck et al.   DIABETOLOGIA

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

(2010) Robert Frederich et al.   POSTGRADUATE MEDICINE

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction

(2009) Marc-Michael Zaruba et al.   Cell Stem Cell

Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

(2009) J. A. DAVIDSON   CLEVELAND CLINIC JOURNAL OF MEDICINE